A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial

Journal of Thoracic Oncology

Volumn 9, Issue 10, 2014, Pages 1494-1503

  Ryan, Brí M ^a   Pine, Sharon R ^b   Chaturvedi, Anil K ^a   Caporaso, Neil ^a   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Inflammation; Lung cancer; Prognosis; Stage 1

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHEMOLUMINESCENCE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOASSAY; INFLAMMATION; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SMOKING; BLOOD; EARLY DIAGNOSIS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; TUMOR RECURRENCE;

AGED; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84925790640     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000278     Document Type: Article

References (59)

1. Kan Q, Jinno S, Yamamoto H, Okayama H. Chemical DNA damage activates p21 WAF1/CIP1-dependent intra-S checkpoint. FEBS Lett 2007;581:5879-5884.
2. Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K. Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Dig Dis Sci 2007;52:2095-2103.
3. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355:479-485.
4. Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000;60:3333-3337.
5. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245-254.
6. U.S.P.T.F. Screening for Lung Cancer U.S. Preventive Services Task Force Recommendation Statement. 2013. Available at: http://www.uspreventiveservicestaskforce.org/uspstf13/lungcan/lungcanfinalrs.htm. Accessed January 30, 2014.
7. Patz EF Jr, Pinsky P, Gatsonis C, et al; NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014;174:269-274.
8. Enewold L, Mechanic LE, Bowman ED, et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009;18:215-222.
9. Alifano M, Falcoz PE, Seegers V, et al. Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg 2011;142:1161-1167.
10. Hong S, Kang YA, Cho BC, Kim DJ. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J 2012;53:111-117.
11. Srimuninnimit V, Ariyapanya S, Nimmannit A, Wonglaksanapimon S, Akewanlop C, Soparattanapaisarn N. C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study). J Med Assoc Thai 2012;95(Suppl 2):S199-S207.
12. Okayama H, Nishimura K, Saito M, et al. Significance of the distal to proximal coronary flow velocity ratio by transthoracic Doppler echocardiography for diagnosis of proximal left coronary artery stenosis. J Am Soc Echocardiogr 2008;21:756-760.
13. Kita H, Shiraishi Y, Watanabe K, et al. Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer? Ann Thorac Cardiovasc Surg 2011;17:454-460.
14. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-267.
15. Vlachostergios PJ, Gioulbasanis I, Kamposioras K, et al. Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients. Oncology 2011;81:113-118.
16. Hijikata A, Kitamura H, Kimura Y, et al. Construction of an open-access database that integrates cross-reference information from the transcriptome and proteome of immune cells. Bioinformatics 2007;23:2934-2941.
17. Turin TC, Kita Y, Rumana N, et al. Registration and surveillance of acute myocardial infarction in Japan: monitoring an entire community by the Takashima AMI Registry: system and design. Circ J 2007;71:1617-1621.
18. Ho LH, Ohno T, Oboki K, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 2007;82:1481-1490.
19. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens: Arsenic, Metals, Fibres, and Dusts. Lyon, France: IARC, 2012. Pp. 100c.
20. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
21. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011;103:1112-1122.
22. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007;25:313-318.
23. Ochiai T, Sonoyama T, Kikuchi S, et al. Results of repeated hepatectomy for recurrent hepatocellular carcinoma. Hepatogastroenterology 2007;54:858-861.
24. Miller AB, Yurgalevitch S, Weissfeld JL; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21(6 Suppl):400S-406S.
25. thedition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474.
26. Wu YW, Tadamura E, Yamamuro M, et al. Estimation of global and regional cardiac function using 64-slice computed tomography: a comparison study with echocardiography, gated-SPECT and cardiovascular magnetic resonance. Int J Cardiol 2008;128:69-76.
27. Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010;28:2719-2726.
28. Cox DR. Regression models and life-tables. J Royal Statistical Soc. Series B (Methodological) 1972;34:187-220.
29. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995;14:1707-1723.
30. Sakata T, Okamoto A, Morita T, et al. Age- and gender-related differences of plasma prothrombin activity levels. Thromb Haemost 2007;97:1052-1053.
31. Savichtcheva O, Okayama N, Okabe S. Relationships between Bacteroides 16S rRNA genetic markers and presence of bacterial enteric pathogens and conventional fecal indicators. Water Res 2007;41:3615-3628.
32. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
33. rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e278S-e313S.
34. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008;3:1468-1481.
35. Seike M, Yanaihara N, Bowman ED, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007;99:1257-1269.
36. Bodelon C, Polley MY, Kemp TJ, et al. Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol 2013;24:2073-2079.
37. Turin TC, Kita Y, Murakami Y, et al Takashima Stroke Registry. Increase of stroke incidence after weekend regardless of traditional risk factors: Takashima Stroke Registry, Japan; 1988-2003. Cerebrovasc Dis 2007;24:328-337.
38. Okayama H, Saito M, Oue N, et al. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression. Int J Cancer 2013;132:9-18.
39. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-285.
40. Wu YW, Tadamura E, Kanao S, et al. Left ventricular functional analysis using 64-slice multidetector row computed tomography: comparison with left ventriculography and cardiovascular magnetic resonance. Cardiology 2008;109:135-142.
41. Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000;6:4739-4744.
42. Munesue S, Yoshitomi Y, Kusano Y, et al. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 2007;282:28164-28174.
43. Shiels MS, Pfeiffer RM, Hildesheim A, et al. Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst 2013;105:1871-1880.
44. Shiels MS, Engels EA, Shi J, et al. Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer 2012;118:5630-5636.
45. Shimzukawa M, Sakakibara T, Sato M, et al. [Tuberculosis in two patients after administration of etanercept for rheumatoid arthritis]. Nihon Naika Gakkai Zasshi 2007;96:1476-1478.
46. Nakamura K, Okamura T, Hayakawa T, et al; NIPPON DATA80, 90 Research Group. The proportion of individuals with obesity-induced hypertension among total hypertensives in a general Japanese population: NIPPON DATA80, 90. Eur J Epidemiol 2007;22:691-698.
47. Takajo I, Umeki K, Morishita K, et al. Engraftment of peripheral blood mononuclear cells from human T-lymphotropic virus type 1 carriers in NOD/SCID/gammac(null) (NOG) mice. Int J Cancer 2007;121:2205-2211.
48. Tatsumi T, Ashihara E, Yasui T, et al. Intracoronary transplantation of non-expanded peripheral blood-derived mononuclear cells promotes improvement of cardiac function in patients with acute myocardial infarction. Circ J 2007;71:1199-1207.
49. Yoneyama S, Miura K, Itai K, et al; INTERMAP Research Group. Dietary intake and urinary excretion of selenium in the Japanese adult population: the INTERMAP Study Japan. Eur J Clin Nutr 2008;62:1187-1193.
50. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-5051.
51. Winton T, Livingston R, Johnson D, et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
52. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010;28:29-34.
53. Kato H, Ichinose Y, Ohta M, et al; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-1721.
54. Roselli M, Mariotti S, Ferroni P, et al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: long-term survival in a randomized study. Int J Cancer 2006;119:955-960.
55. Winton T, Livingston R, Johnson D, et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
56. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
57. Wakelee H, Dubey S, Gandara D. Optimal adjuvant therapy for non-small cell lung cancer - how to handle stage I disease. Oncologist 2007;12:331-337.
58. Takashima N, Shioji K, Kokubo Y, et al. Validation of the association between the gene encoding proteasome subunit alpha type 6 and myocardial infarction in a Japanese population. Circ J 2007;71:495-498.
59. Kido T, Kurata A, Higashino H, et al. Cardiac imaging using 256-detector row four-dimensional CT: preliminary clinical report. Radiat Med 2007;25:38-44.